Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
Provided By GlobeNewswire
Last update: May 8, 2025
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 08, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces the filing of a new composition of matter patent covering a novel solid form of AZD5904, a clinical-stage myeloperoxidase (MPO) inhibitor in the Company’s pipeline.
Read more at globenewswire.com
